The 2024 ADA guidelines recommend GLP-1 RAs as the preferred first-line injectable agents for patients with T2DM and ASCVD or high cardiovascular risk factors, replacing insulin as the primary injectable glucose-lowering therapy. The gene discussed is GLP1R; the disease is atherosclerosis.